VEGF expression may explain aggressiveness of renal cell cancers
May 25th 2005A new study examining the expression of the vascular endothelial growth factor (VEGF) family of proteins in kidney cancer has yielded several important findings, including the identification of different expression profiles of VEGF proteins in clear cell and papillary type renal cell carcinoma.
Prior cancer diagnosis ups future renal cancer risk
May 25th 2005Patients who have other primary cancers have increased risk for renal cancer, the authors of a retrospective study reported yesterday. But while physicians should be alert to the possibility of renal cancer, the risk is not high enough to warrant that all patients in this population should be screened, the authors advise.
Hereditary form of RCC best treated aggressively, study shows
May 25th 2005An inherited syndrome known as hereditary leiomyomatosis and renal cell cancer (HLRCC) has a more aggressive clinical course than other hereditary renal cancer syndromes, according to a new study. The authors recommend surgical therapy early in the course of treatment of HLRCC patients rather than expectant management.
VEGF expression may explain aggressiveness of renal cell cancers
May 25th 2005A new study examining the expression of the vascular endothelial growth factor (VEGF) family of proteins in kidney cancer has yielded several important findings, including the identification of different expression profiles of VEGF proteins in clear cell and papillary type renal cell carcinoma.
Microsurgical varicocelectomy preferred over conservative treatment
May 25th 2005Men who experience painful recurrent varicoceles after undergoing conservative treatment and failed surgical repair are best served by microsurgical varicocelectomy, according to Canadian researchers.Of 11 men who had failed standard varicocelectomy and experienced pain before and after surgery, 10 experienced a favorable response following microsurgical repair, according to investigators."In my mind, microsurgical varicocelectomy is the gold standard, and non-microsurgical repair is sub-standard," said lead author Armand Zini, MD, associate professor of urology at McGill University, Montreal. "However, few urologists are able to perform this procedure, since they have not been trained properly."
Stone disease: Not just a problem in men anymore?
May 25th 2005The prevalence of women being discharged for stone disease has increased in recent years, according to research presented here yesterday. The rate of discharges for men with stone disease over the same period increased slightly for renal calculi and decreased in the case of ureteral calculi.
Botulinum may offer option in BPH, but results are equivocal
May 25th 2005Botulinum toxin A (Botox) injections show potential for providing a quick, easy, and safe treatment option for men with lower urinary tract symptoms related to BPH, but two small studies presented yesterday provided equivocal results regarding the efficacy of this investigational approach. U.S. researchers tested their 10-minute, ultrasound-guided technique in a two-part study. In the first part, 10 patients were injected with botulinum, 100 units, to assess safety, International Prostate Symptom Score, flow rates, and bother scores. In the second part, 30 patients received 200 units of botulinum in a sham-controlled, double-blind study, and sequential MRIs were taken pretreatment and at 1 and 3 months post-treatment to measure prostate volume.
Former Olympian Retton shares her struggle with OAB, launches educational campaign
May 24th 2005For most of her life, former Olympic gymnast Mary Lou Retton suffered from severe urgency and frequency related to overactive bladder. It wasn't until she consulted a urologist just over a year ago that Retton, now 37, received relief from her sometimes debilitating symptoms.Retton has gone public with her personal struggle in a campaign backed by Pfizer. She said she hopes her own experience will help others with the condition seek proper care.
Co-prescription of sildenafil with nitrates still occurs
May 24th 2005A study estimating the dispensation rate of interacting medications to an outpatient population found that while only 0.05% of patients received co-prescriptions for medications that could potentially cause adverse effects, about half of these were given were for sildenafil citrate (Viagra) and one of two different nitrates.
Study shows feasibility of genitofemoral nerve grafts during RP
May 24th 2005Genitofemoral (GF) nerve grafting during radical retropubic prostatectomy can be performed safely with a low risk of postoperative morbidity and shows promising efficacy for returning erectile function after surgery involving wide nerve resection, according to the results of a retrospective study undertaken by urologists from Vanderbilt University, Nashville, TN.
Agent for premature ejaculation shows no interactions with PDE-5 inhibitors
May 24th 2005Dapoxetine, the first treatment developed specifically for premature ejaculation, has no significant interaction when taken concurrently with the type-5 phosphodiesterase type-5 inhibitors sildenafil citrate (Viagra) and tadalafil (Cialis), according to results presented here yesterday.
Docetaxel clears more hurdles in phase II prostate cancer trials
May 24th 2005Data from two separate phase II studies show docetaxel (Taxotere) to be an increasingly promising therapy in the more advanced and aggressive forms of prostate cancer.One study of the agent in prostatectomy patients at high risk of recurrence showed that the drug, administered intravenously, was well tolerated with only two (2.6%) of the 77 patients in the trial experiencing grade IV toxicity (hyperglycemia).
T3 prostate Ca patients appear to be better off with surgery than radiation
May 24th 2005Patients with clinical T3 (cT3) disease are often better off having surgery than going directly to a radiation oncologist, according to a new study.The typical cT3 prostate cancer patient's survival rate is about 79% at 15 years for those who undergo radical prostatectomy , about the same rate as it is at 5 years after radiation therapy without surgery, according to senior study investigator Horst Zincke, MD, PhD, urologist and director of uro-oncologic surgery at the Mayo Clinic, Rochester, MN.
Civil War Medicine exhibit scores a hit
May 23rd 2005It's a 19th century military field hospital at the nucleus of cutting-edge medical therapies, and it's capturing the eyes and minds of AUA attendees. The Civil War Medicine exhibit (Booth 368), sponsored by The William P. Didusch Center for Urologic History of the AUA with support from Lilly ICOS and special contributions from the National Museum of Civil War Medicine, captures the horror and eloquence of military medicine in a remarkable daguerrotype of medical progress from the Civil War to the dawn of the 20th century.
New studies help clarify role of prostate cancer serum markers
May 23rd 2005PSA level remains an excellent marker for prostate cancer, and PSA velocity (PSAV) can be used to determine when to perform a biopsy, according to William J. Catalona, MD, professor of urology, Northwestern University Feinberg School of Medicine, Chicago.
Decade-long Gleason shift may influence study conclusions
May 23rd 2005Prostate cancer studies that compare contemporary outcomes with historic controls should be viewed with the understanding that Gleason scores quietly have been climbing for the past 10 years. This observation is more than a curiosity because clinicians and others use Gleason scores to stage cancers and establish prognoses, and epidemiologists apply them to end results when trying to determine the effect that procedures and therapies have on outcomes.
Prostate biopsy rates fall; TRUS rates rise
May 23rd 2005Biopsy rates, which had soared early in the 1990s with the introduction of the PSA assay, have fallen dramatically and the incidence of prostate cancer has stabilized, according to a study from the University of Southern California, Los Angeles.
Testosterone-corrected PSA density may enhance PCa prediction
May 23rd 2005Findings from a retrospective analysis of men presenting for prostate biopsy because of elevated PSA indicate that an appreciable subset of this population is hypogonadal and suggest those men undergo biopsy at a relatively lower PSA cut-off relative to eugonadal men. Thus, correcting PSA density (PSAD) based on serum testosterone level may improve specificity for cancer detection in men with elevated PSA.
Prostate size linked to reliability of tumor grading
May 23rd 2005Men with larger prostates seem less likely than those with smaller glands to be diagnosed with high-grade cancer at biopsy. However, that size-related difference may reflect sampling artifact, as prostate volume appears not to be a significant predictor of true histologic grade, according to a retrospective study by urologists at the University of Toronto.
Travel guide offered for patients with OAB
May 22nd 2005Travel expert Arthur Frommer has partnered with Novartis Pharmaceuticals Corp. to develop "Where to Stop & Where to Go: A Guide to Traveling with Overactive Bladder in the United States." Available free to people across the United States, the Frommer-authored guide is part of a new educational campaign designed to help people with OAB build confidence about traveling instead of limiting travel because of their condition.
Routine slide reviews in bladder cancer patients need not be routine
May 22nd 2005Although routine, the practice of automatically reviewing pathology slides that accompany referred bladder cancer patients nets little gain for physicians or patients. In an overwhelming majority of instances, the practice does little more than add unnecessarily to the cost of treatment, according to a study presented here yesterday.
Two EPS cytokines may guide chronic prostatitis treatment
May 22nd 2005Measurement of two cytokines in expressed prostatic secretions (EPS) might provide diagnostic guidance for patients with chronic prostatitis/chronic pelvic pain syndrome (CPPS), according to a study presented at the AUA annual meeting.
Prostatecomy using the daVinci robot not currently cost-effective
May 22nd 2005Use of the daVinci robot (Intuitive Surgical, Sunnyvale, CA) for radical prostatectomy procedures is not profitable, according to research presented here yesterday by a team at the University of Rochester Medical Center. However, the researchers say that the costs associated with robotic procedures must eventually come down since the technology is here to stay.